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Letter to the Editor
Sir,
  Vitiligo is a common skin depigmenting disease, 
which is thought to have, at least partly, an autoimmune 
aetiology. The aim of this study was to explore the correlation 
between vitiligo and autoimmune thyroiditis, especially 
Anti-thyroid peroxidase antibody.
Our objective was to compare the frequency of thyroid 
peroxidase antibody (anti-TPO) in vitiligo patients seen in 
2011 in our Department.
Methods
  57 cases of vitiligo (39 women  and 18 men) were 
enrolled in this study,for a period of 12 months (Tabl. I), (Fig. 
1, 2). The clinical type of vitiligo are shown in Table II and 
Fig 3. Anti-TPO levels were assessed in order to detect any 
correlation with the onset, the evolution and the treatment of 
vitiligo.   
Patients with vitiligo and with known thyroid disease, history 
of thyroid surgery and those receiving thyroid medications 
were not included.
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Age (years) Male Female Percentage 
(of the total number of vitiligo patients)
under 6 0 0 0
6-10 0 0 0
10-18 3 2 8,77%
18-30 7 8 26,31%
30-40 2 8 17,54%
40-60 3 19 38,60%
over 60 3 5 14,03%
            Table I. Age and gender distribution of vitiligo patients
Figure. 1 Percentage (of the total number of vitiligo 
patients)
Figure  2.  The  gender  distribution  of  patients  with  vitiligo               
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Clinical forms Number of 
patients with 
vitiligo
Percentage (of the 
total number of 
vitiligo patients)
Number of 
patients with Ac 
TPO within 
normal limits 
(percentage  of 
the total number 
of vitiligo 
patients)
Number of 
patients with Ac 
TPO high levels 
(percentage of the 
total number of 
vitiligo patients)
Number of 
patients with 
unknown value of 
Ac TPO 
(percentage of the 
total number of 
vitiligo patients)
facial 7 12,28% 3 2 2
acro-facial 4 7,01% 1 0 3
focal 27 47,36% 14 5 8
 universal 15 26,31% 6 6 3
acral 4 7,01% 2 2 0
total 57 100% 26 ( 45,6%) 15 (26,31%) 16 (28,07%)
Table II. The clinical type of vitiligo
Of 57 patients with vitiligo: 14 were diagnosed with 
autoimmune thyroiditis meaning of all patients, 13 patients 
were not evaluated for thyroid function and 30 had normal 
thryoid status. (Fig. 4, 5).
Figure 3. Clinical form of vitiligo Figure 4. Thyroid status
Figure 5. Thyroid status of 57 patients
Conclusions
  According to our study, high levels of anti-TPO were 
shown to be more common in vitiligo patients, especially 
in young women. As this antibody is a relatively sensitive 
and specific marker of autoimmune thyroid disorders and 
considering the fact that vitiligo usually precedes the onset of 
thyroid dysfunction, periodic follow-up of vitiligo patients 
for detecting 
thyroid diseases is further emphasized especially in young 
women with increased level of anti-TPO.
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